• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Updates Guidance on Form 1572 Waivers for Foreign Investigators

FDA Updates Guidance on Form 1572 Waivers for Foreign Investigators

May 24, 2021

The FDA has updated its guidance on Form 1572, the FDA’s Statement of Investigator, to clarify what sponsors can or should do if a foreign investigator is unable or unwilling to sign the form.

The guidance was developed in response to sponsor questions on how to proceed if regional, national or local laws or regulations prohibit a foreign investigator from signing the form. One option is to request a waiver from the FDA. Another is to have the foreign site operate as a noninvestigational new drug (IND) site.

The FDA also recommended that sponsors obtain signed, written statements from investigators acknowledging their commitment to comply with any applicable regional, national or local laws.

For sponsors that choose to conduct a foreign clinical study or to operate non-U.S. sites in a multinational study under an IND, the FDA says the foreign investigators would still be in compliance with U.S. regulations if they follow International Council for Harmonization (ICH) E6 Good Clinical Practice guidelines, with two exceptions:

  • FDA requirements for IRBs differ slightly under ICH E6, so sponsors would need to request an additional waiver; and
  • Informed consent requirements for IRBs are more extensive under ICH E6 than under FDA regulations.

Comments on the draft guidance are due by July 19.

Read the FDA guidance here: https://bit.ly/3u79ICC.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing